{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T23:54:04Z","timestamp":1785196444148,"version":"3.55.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2001,5,1]],"date-time":"2001-05-01T00:00:00Z","timestamp":988675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,1,12]]},"abstract":"<jats:title>SUMMARY<\/jats:title>\n               <jats:p>High-dose intravenous immunoglobulin (IVIG) therapy has been effective in many autoimmune and systemic inflammatory diseases including polymyositis (PM) and dermatomyositis (DM). In the present study we evaluated the efficacy of IVIG using experimental models of PM and DM. An experimental autoimmune myositis (EAM) model was produced in SJL\/J mice by an immunization with rabbit myosin B (MB) fraction. In this model, the plasma level of anti-MB antibody was elevated, and mouse IgG and complement C3 were deposited in the muscle fibres. Administration of IVIG dose-dependently reduced the incidences of necrotic and inflammatory changes in the skeletal muscle. IVIG treatment also decreased the elevation of anti-MB antibody level, as well as the deposition of IgG and C3. We next evaluated the effect of IVIG in adoptive EAM mice made by an intravenous injection of lymph node cells previously stimulated with MB. Adoptive EAM mice showed similar lesions in skeletal muscle as EAM mice and IVIG inhibited the lesion development. In vitro experiments demonstrated that IVIG inhibited complement-mediated lysis of human erythrocytes sensitized with anti-human erythrocyte antibodies. The binding of C1q, C4 and C3 to the same cells was also inhibited by IVIG. Taken together these findings suggest that IVIG prevents the development of myositis in EAM and adoptive EAM models by several mechanisms, such as reducing anti-myosin antibody and by blocking complement activation. Our present findings might account for the clinical efficacy of IVIG in PM and DM patients.<\/jats:p>","DOI":"10.1046\/j.1365-2249.2001.01499.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T10:27:01Z","timestamp":1047378421000},"page":"282-289","source":"Crossref","is-referenced-by-count":30,"title":["Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition"],"prefix":"10.1093","volume":"124","author":[{"given":"J","family":"Wada","sequence":"first","affiliation":[{"name":"Drug Discovery Laboratories, Pharmaceutical Research Division, Welfide Corporation, Hirakata, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Shintani","sequence":"additional","affiliation":[{"name":"Drug Discovery Laboratories, Pharmaceutical Research Division, Welfide Corporation, Hirakata, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Kikutani","sequence":"additional","affiliation":[{"name":"Drug Discovery Laboratories, Pharmaceutical Research Division, Welfide Corporation, Hirakata, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Nakae","sequence":"additional","affiliation":[{"name":"Drug Discovery Laboratories, Pharmaceutical Research Division, Welfide Corporation, Hirakata, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Yamauchi","sequence":"additional","affiliation":[{"name":"Drug Discovery Laboratories, Pharmaceutical Research Division, Welfide Corporation, Hirakata, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Takechi","sequence":"additional","affiliation":[{"name":"Drug Discovery Laboratories, Pharmaceutical Research Division, Welfide Corporation, Hirakata, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2002,1,12]]},"reference":[{"key":"2022011305534480200_b1","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJM199111213252107","article-title":"Polymyositis, dermatomyositis, and inclusion-body myositis","volume":"325","author":"Dalakas","year":"1991","journal-title":"N Engl J Med"},{"key":"2022011305534480200_b2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJM198602063140601","article-title":"Microvascular deposition of complement membrane attack complex in dermatomyositis","volume":"314","author":"Kissel","year":"1986","journal-title":"N Engl J Med"},{"key":"2022011305534480200_b3","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/00002281-199611000-00008","article-title":"Update on therapy for refractory dermatomyositis and Polymyositis","volume":"8","author":"Villalba","year":"1996","journal-title":"Curr Opin Rheumatol"},{"key":"2022011305534480200_b4","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"2022011305534480200_b5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/clim.1999.4823","article-title":"Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin","volume":"94","author":"Amemiya","year":"2000","journal-title":"Clin Immunol"},{"key":"2022011305534480200_b6","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1172\/JCI117520","article-title":"High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragment","volume":"94","author":"Basta","year":"1994","journal-title":"J Clin Invest"},{"key":"2022011305534480200_b7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cei.1996.104.s1.3","article-title":"Mechanism of action of intravenous immune globulin in immune-mediated diseases","volume":"104","author":"Mouthon","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"2022011305534480200_b8","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1006\/clin.1993.1082","article-title":"Putative mechanism of the effect of intravenous \u03b3-globulin","volume":"67","author":"Rosen","year":"1993","journal-title":"Clin Immunol Immunopathol"},{"key":"2022011305534480200_b9","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/00005072-198709000-00001","article-title":"Experimental autoimmune inflammatory myopathy","volume":"46","author":"Hart","year":"1987","journal-title":"J Neuropathol Exp Neurol"},{"key":"2022011305534480200_b10","first-page":"117","article-title":"Experimental autoimmune myositis in SJL\/J mice","volume":"68","author":"Rosenberg","year":"1987","journal-title":"Clin Exp Immunol"},{"key":"2022011305534480200_b11","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/BF00227760","article-title":"Experimental allergic myositis in SJL\/J mice immunized with rabbit myosin B fraction: immunohistochemical analysis and transfer","volume":"85","author":"Matsubara","year":"1993","journal-title":"Acta Neuropathol"},{"key":"2022011305534480200_b12","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/BF00692846","article-title":"Experimental allergic myositis: strain 13 guinea pig immunised with rabbit myosin B fraction","volume":"74","author":"Matsubara","year":"1987","journal-title":"Acta Neuropathol"},{"key":"2022011305534480200_b13","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0002-9343(91)90009-M","article-title":"Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study sith 20 adult patients","volume":"91","author":"Cherin","year":"1991","journal-title":"Am J Med"},{"key":"2022011305534480200_b14","first-page":"990","article-title":"The role of intravenous infusions of gamma globulin in the therapy of polymyositis and dermatomyositis","volume":"21","author":"Sussman","year":"1994","journal-title":"J Rheumatol"},{"key":"2022011305534480200_b15","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1212\/WNL.51.6_Suppl_5.S37","article-title":"Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis","volume":"51","author":"Dalakas","year":"1998","journal-title":"Neurology"},{"key":"2022011305534480200_b16","first-page":"94","article-title":"Intravenous immunoglobulin therapy: magic or black magic","volume":"19","author":"Barron","year":"1992","journal-title":"J Rheumatol"},{"key":"2022011305534480200_b17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJM199201093260206","article-title":"Manipulating the immune system with immune globulin","volume":"326","author":"Dwyer","year":"1992","journal-title":"N Engl J Med"},{"key":"2022011305534480200_b18","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0022-510X(96)00223-7","article-title":"Experimental autoimmune myositis in SJL\/J mice produced by immunization with syngeneic myosin B fraction. Transfer by both Immunoglobulin G and T cells","volume":"144","author":"Matsubara","year":"1996","journal-title":"J Neurol Sci"},{"key":"2022011305534480200_b19","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1046\/j.1365-3083.1996.d01-72.x","article-title":"Inhibition of immunoglobulin production in vitro by IgG and F (ab\u2032) 2 fragments, but not by the Fc portion","volume":"43","author":"Klaesson","year":"1996","journal-title":"Scand J Immunol"},{"key":"2022011305534480200_b20","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/BF00918683","article-title":"Suppression of immunoglobulin production of lymphocytes by intravenous immunoglobulin","volume":"11","author":"Kondo","year":"1991","journal-title":"J Clin Immunol"},{"key":"2022011305534480200_b21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-3083.1994.tb03430.x","article-title":"Intravenous immunoglobulins suppress immunoglobulin productions by suppressing Ca2+-dependent signal transduction through Fc\u03b3 receptors in B lymphocytes","volume":"40","author":"Kondo","year":"1994","journal-title":"Scand J Immunol"},{"key":"2022011305534480200_b22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1423-0410.1993.tb02521.x","article-title":"Intravenous immunoglobulin therapy of autoimmune and systemic inflammatory diseases","volume":"64","author":"Ronda","year":"1993","journal-title":"Vox Sang"},{"key":"2022011305534480200_b23","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0140-6736(84)90701-3","article-title":"Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin","volume":"2","author":"Sultan","year":"1984","journal-title":"Lancet"},{"key":"2022011305534480200_b24","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1182\/blood.V74.7.2414.2414","article-title":"Inhibition of autoantibody bindinb to platelet glycoprotein IIb\/IIIa by anti-idiotypic antibodies in intravenous immunoglobulins","volume":"74","author":"Berchtold","year":"1989","journal-title":"Blood"},{"key":"2022011305534480200_b25","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1365-3083.1995.tb03591.x","article-title":"Inhibition of complement-madeated red cell lysis by immunoglobulins is dependent on the IG isotype and its C1 binding properties","volume":"41","author":"Mollnes","year":"1995","journal-title":"Scand J Immunol"},{"key":"2022011305534480200_b26","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood.V77.2.376.376","article-title":"High doses of intravenous Ig inhibit in vitro uptake pf C4 fragments onto sensitized erythrocytes","volume":"77","author":"Basta","year":"1991","journal-title":"Blood"},{"key":"2022011305534480200_b27","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1016\/S0021-9258(18)53400-1","article-title":"Identification of a major binding site for complement C3 on the IgG1 heavy chain","volume":"268","author":"Shohet","year":"1993","journal-title":"J Biol Chem"},{"key":"2022011305534480200_b28","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/eji.1830240316","article-title":"C3 binds with similar efficiency to Fab and Fc regions of IgG immune aggregates","volume":"24","author":"Anton","year":"1994","journal-title":"Eur J Immunol"},{"key":"2022011305534480200_b29","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0161-5890(97)00091-6","article-title":"Effect of whole and fractionated intravenous immunoglobulin on complement in vitro","volume":"34","author":"Mollnes","year":"1997","journal-title":"Mol Immunol"},{"key":"2022011305534480200_b30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0952-7915(95)80027-1","article-title":"Complement\u2013immunoglobulin interactions","volume":"7","author":"Miletic","year":"1995","journal-title":"Curr Opin Immunol"},{"key":"2022011305534480200_b31","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1182\/blood.V78.3.700.700","article-title":"High doses of intravenous immunoglobulin do not affect the recognition phase of the classical complement pathway","volume":"78","author":"Basta","year":"1991","journal-title":"Blood"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2249.2001.01499.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2249.2001.01499.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/124\/2\/282\/42162930\/j.1365-2249.2001.01499.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/124\/2\/282\/42162930\/j.1365-2249.2001.01499.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T11:49:37Z","timestamp":1676375377000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/124\/2\/282\/6461461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,5]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2002,1,12]]},"published-print":{"date-parts":[[2002,1,12]]}},"URL":"https:\/\/doi.org\/10.1046\/j.1365-2249.2001.01499.x","relation":{},"ISSN":["1365-2249","0009-9104"],"issn-type":[{"value":"1365-2249","type":"electronic"},{"value":"0009-9104","type":"print"}],"subject":[],"published-other":{"date-parts":[[2001,5]]},"published":{"date-parts":[[2001,5]]}}}